<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="tardbp-als" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">tardbp-als</book-part-id>
      <title-group>
        <title><italic toggle="yes">TARDBP</italic>-Related Amyotrophic Lateral Sclerosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Harms</surname>
            <given-names>Matthew M</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Neurology<break/>Neuromuscular Division<break/>Washington University School of Medicine<break/>St Louis, Missouri</aff>
          <email>harmsm@neuro.wustl.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Miller</surname>
            <given-names>Timothy M</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Neurology<break/>Neuromuscular Division<break/>Washington University School of Medicine<break/>St Louis, Missouri</aff>
          <email>millert@neuro.wustl.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baloh</surname>
            <given-names>Robert H</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Neurology<break/>Cedars Sinai Medical Center<break/>Los Angeles, California</aff>
          <email>robert.baloh@csmc.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>23</day>
          <month>4</month>
          <year>2009</year>
        </date>
        <date date-type="updated">
          <day>12</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>28</day>
          <month>5</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cdsp" document-type="chapter">Systemic Primary Carnitine Deficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="tbc1d24-dis" document-type="chapter">
<italic toggle="yes">TBC1D24</italic>-Related Disorders</related-object>
      <abstract id="tardbp-als.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">TARDBP</italic>-related amyotrophic lateral sclerosis (<italic toggle="yes">TARDBP</italic>-related ALS) is characterized by upper motor neuron (UMN) and lower motor neuron (LMN) disease that appears indistinguishable from ALS of other known and unknown causes based on gender ratio, age of onset, symptom distribution, and severity of disease. The male to female ratio is 1.6 to 1. Mean age of onset is 54 &#x000b1; 12 years. UMN manifestations can include stiffness, spasticity, hyperreflexia, and pseudobulbar affect; LMN manifestations often include weakness accompanied by muscle atrophy, fasciculations, and cramping. Limb onset occurs in 80% and bulbar onset in 20%. Affected individuals typically succumb to respiratory failure when phrenic and thoracic motor neurons become severely involved.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of ALS is established by clinical examination, neurophysiologic testing, and neuroimaging. <italic toggle="yes">TARDBP</italic> is the only gene associated with <italic toggle="yes">TARDBP</italic>-related ALS.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Spasticity can be treated with a spasmolytic such as baclofen or a benzodiazepine; pseudobulbar affect can be treated with a tricyclic antidepressant or combination of quinidine and dextromethorphan; sialorrhea is often managed with anticholinergic medications (tricyclic antidepressants, scopolamine, atropine drops) or botulinum toxin injection of the salivary glands; antidepressants are often required to treat concurrent depression; it is reasonable to consider use of riluzole, the only FDA-approved treatment for any type of ALS.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Percutaneous gastrostomy can be used to maintain adequate caloric intake in persons with significant bulbar involvement; appropriate bracing and stretching can minimize contractures; noninvasive ventilation can be initiated when appropriate.</p>
          <p><italic toggle="yes">Surveillance:</italic> At clinic visits: monitoring of ventilatory function and screening for depression.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Long-term use of minocycline; excessive exercise to the point of inducing fatigue.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">TARDBP</italic>-related ALS is inherited in an autosomal dominant manner. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown. Each child of an individual with <italic toggle="yes">TARDBP</italic>-related ALS has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for <italic toggle="yes">TARDBP</italic>-related ALS is possible if the pathogenic variant has been identified in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="tardbp-als.Diagnosis">
        <title>Diagnosis</title>
        <p>A diagnosis of <italic toggle="yes">TARDBP</italic>-related amyotrophic lateral sclerosis (<italic toggle="yes">TARDBP</italic>-related ALS) is established when a <italic toggle="yes">TARDBP</italic> pathogenic variant is identified in an individual meeting clinical diagnostic criteria for ALS (i.e., characteristic signs and symptoms of progressive degeneration of upper motor neurons (UMNs) and lower motor neurons [LMNs]).</p>
        <list list-type="bullet">
          <list-item>
            <p>UMN manifestations include stiffness, spasticity, hyperreflexia, and pseudobulbar affect</p>
          </list-item>
          <list-item>
            <p>LMN manifestations include weakness accompanied by muscle atrophy, fasciculations, and cramping</p>
          </list-item>
        </list>
        <p>(See the El Escorial criteria [<xref ref-type="bibr" rid="tardbp-als.REF.brooks.2000.293">Brooks et al 2000</xref>].)</p>
        <p>Note: <italic toggle="yes">TARDBP-</italic>related ALS is clinically indistinguishable from ALS due to other causes.</p>
        <p>See <related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object> for a more detailed description of these features.</p>
        <sec id="tardbp-als.Testing">
          <title>Testing</title>
          <p>Clinical testing in <italic toggle="yes">TARDBP</italic>-related ALS is identical to that for other forms of ALS, employing multiple modalities to exclude alternative diagnoses and to provide support for the diagnosis of ALS. Following a diagnosis of ALS, genetic testing for <italic toggle="yes">TARDBP</italic> pathogenic variants can be considered (see <xref ref-type="sec" rid="tardbp-als.Testing_Strategy">Testing Strategy</xref>).</p>
          <p><bold>Electromyography and nerve conduction studies (EMG/NCS).</bold> EMG/NCS are often used to support a diagnosis of ALS and to exclude mimics of ALS (e.g., polyradiculopathy, mononeuritis multiplex, multifocal motor neuropathy, sensory motor neuropathies). EMG/NCS in <italic toggle="yes">TARDBP-</italic>related ALS, as in other causes of ALS, demonstrates widespread denervation due to LMN loss in the setting of relatively preserved sensory responses [<xref ref-type="bibr" rid="tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</xref>].</p>
          <p><bold>Neuroimaging.</bold> MRI of the brain and spinal cord are used in the evaluation to exclude alternate explanations for the observed symptoms, including polyradiculopathy and spinal cord or brain lesions. Although several imaging abnormalities have been directly attributed to ALS, including abnormal T<sub>2</sub> signal along the corticospinal tracts and atrophy of the precentral gyrus, the poor sensitivity and specificity of these findings limit their usefulness in confirming the diagnosis of ALS [<xref ref-type="bibr" rid="tardbp-als.REF.grosskreutz.2008.238">Grosskreutz et al 2008</xref>]. If frontotemporal dementia is also present, atrophy of the frontal and temporal lobes may be present [<xref ref-type="bibr" rid="tardbp-als.REF.floris.2015.375">Floris et al 2015</xref>]. Although the imaging characteristics of <italic toggle="yes">TARDBP</italic>-related ALS have not been systematically investigated, single cases have had unremarkable MRI of the brain and cervical spinal cord [<xref ref-type="bibr" rid="tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.pamphlett.2009.222">Pamphlett et al 2009</xref>].</p>
          <p><bold>Cerebrospinal fluid (CSF).</bold> Analysis of the CSF is primarily used to exclude conditions with overlapping features of ALS, including infectious polyradiculitis and carcinomatosis or lymphomatosis. TAR DNA-binding protein 43 (TDP-43), the protein encoded by <italic toggle="yes">TARDBP</italic>, has been detected in the CSF of individuals with ALS of unknown cause [<xref ref-type="bibr" rid="tardbp-als.REF.steinacker.2008.1481">Steinacker et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kasai.2009.55">Kasai et al 2009</xref>]. It has only been examined in a single individual with <italic toggle="yes">TARDBP-</italic>related ALS, and this individual had substantially higher levels than individuals with sporadic ALS [<xref ref-type="bibr" rid="tardbp-als.REF.nozaki.2010.1209">Nozaki et al 2010</xref>].</p>
          <p><bold>Neuropathology.</bold> Pathologic evaluation of the brain and spinal cord can be utilized to confirm a diagnosis of ALS post mortem. One of the pathologic hallmarks of ALS is the presence of ubiquitin-immunoreactive cytoplasmic inclusions in degenerating cortical and spinal cord neurons. In non-<italic toggle="yes">SOD1</italic> ALS (including <italic toggle="yes">TARBP</italic>-associated ALS), these cytoplasmic inclusions typically contain TDP-43, which is also reduced or absent from the nuclei of inclusion-containing cells [<xref ref-type="bibr" rid="tardbp-als.REF.neumann.2006.130">Neumann et al 2006</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.davidson.2007.521">Davidson et al 2007</xref>]. However, TDP-43-positive inclusions are not specific for ALS and have also been described in other neurodegenerative diseases [<xref ref-type="bibr" rid="tardbp-als.REF.freeman.2008.62">Freeman et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.uryu.2008.555">Uryu et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.arai.2009.125">Arai et al 2009</xref>] and in several diseases of muscle [<xref ref-type="bibr" rid="tardbp-als.REF.weihl.2008.1186">Weihl et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.k_sters.2009.209">K&#x000fc;sters et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.oliv_.2009.262">Oliv&#x000e9; et al 2009</xref>].</p>
        </sec>
        <sec id="tardbp-als.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">TARDBP</italic> is the only gene in which pathogenic variants are known to cause <italic toggle="yes">TARDBP</italic>-related ALS.</p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="tardbp-als.T.summary_of_molecular_geneti" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">TARDBP</italic>-Related Amyotrophic Lateral Sclerosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">TARDBP</italic>
                  </td>
                  <td headers="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Approaches 100%&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_tardbp-als.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 5</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="tardbp-als.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="tardbp-als" object-id="tardbp-als.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="tardbp-als.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="tardbp-als.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="tardbp-als.TF.1.3">
                <label>3. </label>
                <p>Because <italic toggle="yes">TARDBP</italic>-related ALS is defined by the presence of a pathogenic variant in <italic toggle="yes">TARDBP</italic>, and because variant types that are not detected by <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</ext-link> (e.g., exon or whole-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/gene/">gene</ext-link> deletions) have not been reported, the variant detection rate for <italic toggle="yes">TARDBP</italic> using sequence analysis approaches 100%.</p>
              </fn>
              <fn id="tardbp-als.TF.1.4">
                <label>4. </label>
                <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="tardbp-als.TF.1.5">
                <label>5. </label>
                <p>No large deletions or insertions have been reported. Screening for these types of variants has been reported in 714 patients using rt-PCR or multiplexed amplicon quantification (MAQ) [<xref ref-type="bibr" rid="tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.rutherford.2008.e1000193">Rutherford et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.b_umer.2009.1283">B&#x000e4;umer et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.benajiba.2009.470">Benajiba et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.gijselinck.2009.1329">Gijselinck et al 2009</xref>]. Since the proposed mechanism that leads to <italic toggle="yes">TARDBP</italic>-related ALS is gain-of-function of TARDBP, it is unlikely that copy number variants in <italic toggle="yes">TARDBP</italic> will comprise a significant number of cases.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="tardbp-als.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Establish a clinical diagnosis of ALS using clinical examination, neurophysiologic testing, and neuroimaging. Note: <italic toggle="yes">TARDBP-</italic>related ALS is clinically indistinguishable from ALS resulting from other causes.</p>
            </list-item>
            <list-item>
              <p>Obtain a three-generation family history. The presence of ALS in a closely related family member (usually a parent) increases the probability that a <italic toggle="yes">TARDBP</italic> pathogenic variant may be found. If the proband is the only occurrence of ALS in their family, i.e. a simplex case, the likelihood of identifying a <italic toggle="yes">TARDBP</italic> pathogenic variant is lower.</p>
              <p>Note: (1) To date, all reported pedigrees with <italic toggle="yes">TARDBP</italic>-related ALS show autosomal dominant inheritance; (2) Several genetic causes of ALS are more common than <italic toggle="yes">TARDBP</italic>-related ALS (see below).</p>
            </list-item>
          </list>
          <p>
            <bold>Familial ALS (FALS) (i.e., presence of at least two affected family members)</bold>
          </p>
          <p><bold>Single-gene testing.</bold> One genetic testing strategy is serial single-gene molecular genetic testing based on the order in which pathogenic variants most commonly occur.</p>
          <list list-type="bullet">
            <list-item>
              <p>In most white populations, molecular genetic testing in the following order is recommended:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Testing for an expansion of the hexanucleotide repeat in <italic toggle="yes">C9ORF72</italic> (accounting for ~40%-50% of FALS) should be done first.</p>
                </list-item>
                <list-item>
                  <p>If no expansion is identified in <italic toggle="yes">C9ORF72</italic>, molecular genetic testing of <italic toggle="yes">SOD1</italic> (accounting for ~20% of FALS) should be considered next.</p>
                </list-item>
                <list-item>
                  <p>If molecular genetic testing of <italic toggle="yes">C9ORF72</italic> and <italic toggle="yes">SOD1</italic> does not reveal a pathogenic variant, molecular genetic testing of <italic toggle="yes">TARDBP</italic> and/or <italic toggle="yes">FUS</italic> (together accounting for &#x0003c;5% of cases) should be considered next<italic toggle="yes">.</italic></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In individuals of Asian or African background, molecular genetic testing of <italic toggle="yes">SOD1</italic> should be considered first<italic toggle="yes">.</italic></p>
            </list-item>
            <list-item>
              <p>In Sardinia, where <italic toggle="yes">C9ORF72</italic> expansions and <italic toggle="yes">TARDBP</italic> pathogenic variants account for most cases and at times coexist in the same family, simultaneous molecular genetic testing of both genes could be considered.</p>
            </list-item>
          </list>
          <p><bold>Multi-gene panel.</bold> An alternative genetic testing strategy is use of a multi-gene panel that includes <italic toggle="yes">C9ORF72, SOD1</italic>, <italic toggle="yes">TARDBP</italic>, and other genes of interest (see <xref ref-type="sec" rid="tardbp-als.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
          <p><bold>More comprehensive genomic testing.</bold> (when available) including exome sequencing, genome sequencing and mitochondrial sequencing may be considered if single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of ALS. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
          <p><bold>Other.</bold> In some cases testing for other rare genetic causes of FALS can be considered, although these typically have a distinctive clinical presentation or autosomal recessive inheritance pattern (see <related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object>).</p>
          <p>
            <bold>Simplex/sporadic ALS (SALS) (i.e., single occurrence in a family)</bold>
          </p>
          <p>Sequencing of <italic toggle="yes">TARDBP</italic> in SALS can be performed, but the lower mutation prevalence (1.1%) in this population should be taken into consideration.</p>
        </sec>
      </sec>
      <sec id="tardbp-als.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="tardbp-als.Clinical_Description">
          <title>Clinical Description</title>
          <p>More than 200 individuals with <italic toggle="yes">TARDBP-</italic>related ALS have been described in the literature. The spectrum of clinical disease has been defined by a recent analysis of all published reports of individuals with a <italic toggle="yes">TARDBP</italic> pathogenic variant, noting substantial differences between Asian and non-Asian individuals [<xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>].</p>
          <p>The average age of symptom onset is 53.5 &#x000b1; 12.3 years (mean &#x000b1; SD), which is similar to affected individuals with <italic toggle="yes">SOD1</italic> pathogenic variants but substantially earlier than those with simplex ALS and familial ALS without an identified pathogenic variant.</p>
          <p>Most individuals with <italic toggle="yes">TARDBP</italic>-related ALS have both UMN and LMN involvement and during disease course will meet El Escorial criteria for ALS [<xref ref-type="bibr" rid="tardbp-als.REF.brooks.2000.293">Brooks et al 2000</xref>]. Although predominantly LMN involvement is common [<xref ref-type="bibr" rid="tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>], no individuals with pure UMN involvement (i.e. primary lateral sclerosis) have been reported.</p>
          <p>More than half of non-Asian individuals with a <italic toggle="yes">TARDBP</italic> pathogenic variant have first symptoms in the upper extremities, a rate that is double that found in other forms of the disease. However, bulbar onset appears to predominate in Asian individuals [<xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>] and intra- and interfamilial variability in the site of onset is observed even with the same pathogenic variant (see <xref ref-type="sec" rid="tardbp-als.GenotypePhenotype_Correlation">Genotype-Phenotype Correlations</xref>).</p>
          <p>As with other forms of ALS, individuals with <italic toggle="yes">TARDBP-</italic>related ALS die of respiratory failure when phrenic and thoracic motor neurons become severely involved. However, the median disease survival in non-Asian individuals with a <italic toggle="yes">TARDBP</italic> pathogenic variant is 62 months, which is significantly longer than the survival of individuals without a known <italic toggle="yes">TARDBP</italic> pathogenic variant, either with simplex ALS (35 months) or familial ALS (31 months). Interestingly, Asian individuals with a <italic toggle="yes">TARDBP</italic> pathogenic variant appear to have even slower rates of progression of disease, with median disease duration of 108 months [<xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>]. Disease duration is also influenced by which pathogenic variant is present, and although the median survival is favorable, progression to death within a year is not uncommon (see <xref ref-type="sec" rid="tardbp-als.GenotypePhenotype_Correlation">Genotype-Phenotype Correlations</xref>).</p>
          <p>Although these trends are visible in aggregated cohorts of affected individuals, the range of age at onset, pattern of symptoms at onset, and disease duration are quite broad and substantially overlap with all other causes of ALS. As a result, phenotypic features do little to inform whether genetic testing should be pursued.</p>
        </sec>
        <sec id="tardbp-als.GenotypePhenotype_Correlation">
          <title>Genotype-Phenotype Correlations</title>
          <p>Correlations between specific pathogenic variants and clinical phenotype are available for only the most commonly reported pathogenic variants in <italic toggle="yes">TARDBP.</italic> For the vast majority of pathogenic variants, the numbers are too few to draw reliable conclusions. However:</p>
          <list list-type="bullet">
            <list-item>
              <p>As predicted by early reports, the <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Gly298Ser</xref> pathogenic variant demonstrates an earlier age of onset (mean 50.7 years) and the most rapid rate of progression of disease (mean 27 months) [<xref ref-type="bibr" rid="tardbp-als.REF.van_deerlin.2008.409">Van Deerlin et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>The <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Ala315Thr</xref> pathogenic variant was initially reported in two families with a slowly progressive limb-only LMN-predominant phenotype [<xref ref-type="bibr" rid="tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>]. Large groups of individuals with this pathogenic variant now confirm a much later age at onset (mean 66 years) and much longer survival (mean 110 months) [<xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Other more common pathogenic variants including <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Ala382Thr</xref>, <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Met337Val</xref>, and <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Gly348Cys</xref> are intermediate in their average ages at onset and survival times [<xref ref-type="bibr" rid="tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Within families, no genotype-phenotype correlations have been made with regard to site of onset, with both limb onset and bulbar onset being observed in the same family.</p>
            </list-item>
            <list-item>
              <p>Disparate sites of onset were seen in unrelated persons with the same pathogenic variant, including the following: <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Gly287Ser</xref> [<xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>], <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Gly294Val</xref> [<xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</xref>], and <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Ala382Thr</xref> [<xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="tardbp-als.Penetrance">
          <title>Penetrance</title>
          <p>Like pathogenic variants in other ALS-related genes (e.g., <italic toggle="yes">SOD1</italic>), penetrance is clearly incomplete. This is evident from the number of individuals with apparently simplex ALS who have a <italic toggle="yes">TARDBP</italic> pathogenic variant, which may have been inherited from an ostensibly asymptomatic (or undiagnosed) parent. However, accurate estimates are difficult to achieve for the following reasons:</p>
          <list list-type="bullet">
            <list-item>
              <p>Few unaffected individuals in families with <italic toggle="yes">TARDBP</italic>-related ALS have been genotyped or longitudinally followed for the emergence of symptoms.</p>
            </list-item>
            <list-item>
              <p>The parents and relatives of apparently simplex ALS cases with <italic toggle="yes">TARDBP</italic> pathogenic variants have not been reported in detail.</p>
            </list-item>
          </list>
        </sec>
        <sec id="tardbp-als.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of <italic toggle="yes">TARDBP</italic> pathogenic variants in:</p>
          <list list-type="bullet">
            <list-item>
              <p>All individuals with ALS (FALS and SALS) is 1.6% (49/3108 persons);</p>
            </list-item>
            <list-item>
              <p>FALS is 3.4% (21/618 probands), but ranges from 0% to 12% across studies [<xref ref-type="bibr" rid="tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.gijselinck.2009.1329">Gijselinck et al 2009</xref>];</p>
            </list-item>
            <list-item>
              <p>SALS is 1.1% but ranges from 0% to 5% across studies [<xref ref-type="bibr" rid="tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>].</p>
            </list-item>
          </list>
          <p>Pathogenic variants in <italic toggle="yes">TARDBP</italic> have been reported worldwide:</p>
          <list list-type="bullet">
            <list-item>
              <p>North America [<xref ref-type="bibr" rid="tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p>Europe [<xref ref-type="bibr" rid="tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.sreedharan.2008.1668">Sreedharan et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.daoud.2009.112">Daoud et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</xref>]</p>
            </list-item>
            <list-item>
              <p>Japan [<xref ref-type="bibr" rid="tardbp-als.REF.yokoseki.2008.538">Yokoseki et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p>China [<xref ref-type="bibr" rid="tardbp-als.REF.van_deerlin.2008.409">Van Deerlin et al 2008</xref>]</p>
            </list-item>
          </list>
          <p>A higher prevalence in Italian, French, and Taiwanese populations has been reported [<xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.daoud.2009.112">Daoud et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</xref>]. The <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Ala382Thr</xref> pathogenic variant is very common in Sardinia due to a founder effect. It accounts for 80% of familial ALS and 9% of simplex cases [<xref ref-type="bibr" rid="tardbp-als.REF.orr_.2012.172">Orr&#x000f9; et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="tardbp-als.Genetically_Related_Allelic_D">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Although typical ALS is the predominant phenotype associated with <italic toggle="yes">TARDBP</italic> pathogenic variants, individuals with <italic toggle="yes">TARDBP</italic> pathogenic variants can also present with frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) and rarely with frontotemporal dementia without motor neuron loss [<xref ref-type="bibr" rid="tardbp-als.REF.borroni.2010.509">Borroni et al 2010</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.synofzik.2014.1212.e1">Synofzik et al 2014</xref>]. Because individuals with a <italic toggle="yes">TARDBP</italic> pathogenic variant can have some extrapyramidal symptoms, molecular genetic testing has also identified a few individuals with parkinsonism but no motor neuron loss [<xref ref-type="bibr" rid="tardbp-als.REF.rayaprolu.2013.312">Rayaprolu et al 2013</xref>].</p>
      </sec>
      <sec id="tardbp-als.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>For a detailed discussion of these disorders and the differential diagnosis of ALS, see <related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object>.</p>
        <p><italic toggle="yes">TARDBP</italic>-associated ALS must be differentiated from conditions that have overlapping features of ALS. Detailed clinical evaluation (as outlined above) is usually sufficient to exclude other disorders. The rate of misdiagnosis in ALS is highest in individuals presenting with purely LMN findings [<xref ref-type="bibr" rid="tardbp-als.REF.traynor.2000.109">Traynor et al 2000</xref>].</p>
        <p>The mimics of ALS from any cause are numerous and include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Multifocal motor neuropathy</p>
          </list-item>
          <list-item>
            <p>Cervical spondylosis</p>
          </list-item>
          <list-item>
            <p>Adult-onset <related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">spinal muscular atrophy</related-object> (SMA)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="kennedy" document-type="chapter">Kennedy disease</related-object> (X-linked spinobulbar muscular atrophy [SBMA])</p>
          </list-item>
          <list-item>
            <p>Acquired and hereditary motor neuropathies (see <related-object link-type="booklink" source-id="gene" document-id="cmt" document-type="chapter">Charcot-Marie-Tooth Hereditary Neuropathy Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p>Late-onset GM2 gangliosidosis (see <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">Hexosaminidase A Deficiency</related-object>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="apbd" document-type="chapter">Adult polyglucosan body disease</related-object>
            </p>
          </list-item>
        </list>
        <p>The number of other genes associated with FALS (see note) has been rapidly increasing and is tracked at the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://alsod.iop.kcl.ac.uk/">ALSoD site</ext-link>. Some examples include:</p>
        <list list-type="bullet">
          <list-item>
            <p>ALS1. <italic toggle="yes">SOD1</italic> (encoding the protein superoxide dismutase)</p>
          </list-item>
          <list-item>
            <p>ALS4. <italic toggle="yes">SETX</italic> (encoding the protein probable helicase senataxin)</p>
          </list-item>
          <list-item>
            <p>ALS6. <italic toggle="yes">FUS/TLS</italic> (encoding the protein )</p>
          </list-item>
          <list-item>
            <p>ALS8. <italic toggle="yes">VAPB</italic> (encoding the protein vesicle-associated membrane protein-associated protein B/C)</p>
          </list-item>
          <list-item>
            <p>ALS9. <italic toggle="yes">ANG</italic> (encoding the protein angiogenin)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">DCTN1</italic> (encoding the protein dynactin subunit 1)</p>
          </list-item>
        </list>
        <p>Note: Pathogenic variants in many of these genes have also been identified in small numbers of simplex cases of ALS (i.e., a single occurrence in a family).</p>
      </sec>
      <sec id="tardbp-als.Management">
        <title>Management</title>
        <sec id="tardbp-als.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">TARDBP</italic>-related ALS (or any other form of ALS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>EMG/NCS to document the regions of involvement</p>
            </list-item>
            <list-item>
              <p>Pulmonary function testing to detect and stage respiratory involvement</p>
            </list-item>
            <list-item>
              <p>Speech and swallowing evaluation if dysarthria and/or dysphagia are present, to direct care to minimize risk of aspiration and to initiate augmentative communication strategies for possible loss of verbal communication</p>
            </list-item>
            <list-item>
              <p>Physical and occupational therapy evaluation to determine what adaptive devices are needed to maximize function</p>
            </list-item>
            <list-item>
              <p>Nutritional evaluation</p>
            </list-item>
            <list-item>
              <p>Screening for depression and need for psychosocial support</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="tardbp-als.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The management of <italic toggle="yes">TARDBP</italic>-related ALS is identical to that of ALS resulting from other causes, and is outlined in the American Academy of Neurology practice parameter on this topic [<xref ref-type="bibr" rid="tardbp-als.REF.miller.2009a.1218">Miller et al 2009a</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.miller.2009b.1227">Miller et al 2009b</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Spasticity can be treated with a spasmolytic such as baclofen or a benzodiazepine.</p>
            </list-item>
            <list-item>
              <p>Pseudobulbar affect can be treated with a tricyclic antidepressant or combination of quinidine and dextromethorphan.</p>
            </list-item>
            <list-item>
              <p>Sialorrhea is often managed with anticholinergic medications (tricyclic antidepressants, scopolamine, atropine drops) or botulinum toxin injection of the salivary glands.</p>
            </list-item>
            <list-item>
              <p>Antidepressants are often required to treat concurrent depression.</p>
            </list-item>
            <list-item>
              <p>Riluzole is the only FDA-approved treatment for any type of ALS. Although there are no efficacy data specifically for <italic toggle="yes">TARDBP</italic>-related ALS, strong consideration should be given to its use [<xref ref-type="bibr" rid="tardbp-als.REF.miller.2007.cd001447">Miller et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>Note: See <xref ref-type="sec" rid="tardbp-als.Author_Notes">Author Notes</xref>, Miller Laboratory for a link to investigative reports on accurate assessments of the risks and benefits of specific proposed therapies.</p>
        </sec>
        <sec id="tardbp-als.Prevention_of_Secondary_Compl">
          <title>Prevention of Secondary Complications</title>
          <p>Adequate nutrition and weight maintenance are essential. Percutaneous gastrostomy is often appropriate to maintain adequate caloric intake in persons with significant bulbar involvement.</p>
          <p>Joint contractures can occur, are often painful, and can interfere with care giving. Appropriate bracing and stretching can minimize contractures.</p>
          <p>Early initiation of noninvasive ventilation has been shown to prolong survival [<xref ref-type="bibr" rid="tardbp-als.REF.farrero.2005.2132">Farrero et al 2005</xref>].</p>
        </sec>
        <sec id="tardbp-als.Surveillance">
          <title>Surveillance</title>
          <p>Monitoring of the forced vital capacity and other parameters of ventilation should be performed at clinic visits to determine the appropriate time to offer noninvasive ventilation.</p>
          <p>Routine screening for depression at clinic visits is appropriate.</p>
        </sec>
        <sec id="tardbp-als.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Long-term use of minocycline, which was studied in a randomized-controlled trial in individuals with ALS, was associated with worse outcomes [<xref ref-type="bibr" rid="tardbp-als.REF.gordon.2007.1045">Gordon et al 2007</xref>].</p>
          <p>Excessive exercise to the point of inducing fatigue in already weakened muscles is cautioned against by many practitioners based on experience.</p>
        </sec>
        <sec id="tardbp-als.Evaluation_of_Relatives_at_Ri">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="tardbp-als.Related_Genetic_Counseling_Is">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="tardbp-als.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Although no current clinical trials are specifically designed to target <italic toggle="yes">TARDBP</italic>-related ALS, many ongoing trials address the broader category of ALS.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="tardbp-als.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="tardbp-als.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">TARDBP</italic>-related amyotrophic lateral sclerosis is usually inherited in an autosomal dominant manner. In very rare instances, an affected individual may have biallelic pathogenic variants in <italic toggle="yes">TARDBP</italic> [<xref ref-type="bibr" rid="tardbp-als.REF.borghero.2011.2327.e1">Borghero et al 2011</xref>] or may have digenic pathogenic variants (i.e., a pathogenic variant in <italic toggle="yes">TARDBP</italic> with a coexisting repeat expansion in <italic toggle="yes">C9ORF72</italic> [<xref ref-type="bibr" rid="tardbp-als.REF.van_blitterswijk.2012.3776">van Blitterswijk et al 2012</xref>]).</p>
        </sec>
        <sec id="tardbp-als.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Many individuals diagnosed with <italic toggle="yes">TARDBP</italic>-related ALS have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with <italic toggle="yes">TARDBP</italic>-related ALS may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The frequency of <italic toggle="yes">TARDBP de novo</italic> pathogenic variants is unknown because relatives of simplex cases have not been sufficiently evaluated to exclude low penetrance.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent de novo pathogenic variant include thorough neurologic evaluation and molecular genetic testing for the <italic toggle="yes">TARDBP</italic> pathogenic variant identified in the proband. Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>Note: (1) Although most individuals diagnosed with TARDBP-related ALS have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset or reduced penetrance of the disease in the affected parent. (2) If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs of inheriting the <italic toggle="yes">TARDBP</italic> pathogenic variant is 50%.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk (for the disorder) because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population, because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with <italic toggle="yes">TARDBP</italic>-related ALS has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected or has a <italic toggle="yes">TARDBP</italic> pathogenic variant, his or her family members may be at risk.</p>
        </sec>
        <sec id="tardbp-als.Related_Genetic_Counseling_Is">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the pathogenic variant occurred <italic toggle="yes">de novo</italic> in the proband. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Testing of at-risk asymptomatic adults.</bold> Presymptomatic testing for a <italic toggle="yes">TARDBP</italic> pathogenic variant is complicated because the penetrance is unknown, the age of onset is not predictable, and preventive measures do not exist. Because of the individualized nature of predictive testing, consultation with a genetic counselor and a psychologist to obtain informed consent is recommended. At this time, no established testing protocol (e.g., as in <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object>) exists, although establishment of such protocols has been suggested. However, to err on the side of caution, testing centers often follow a similar protocol.</p>
          <p><bold>Testing of at-risk individuals during childhood.</bold> Consensus holds that asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders should not have molecular genetic testing. The principal reasons against testing such individuals are that testing removes their choice to know or not know this information, it raises the possibility of stigmatization within the family and in other social settings, and it could have serious educational and career implications. In addition, no preventive treatment is available for ALS. See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p>Individuals younger than age 18 years who are symptomatic usually benefit from having a specific diagnosis established.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="tardbp-als.Prenatal_Testing_and_Preimpla">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">TARDBP</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for <italic toggle="yes">TARDBP</italic>-related ALS are possible.</p>
          <p>Requests for prenatal testing for adult-onset conditions (like <italic toggle="yes">TARDBP</italic>-related ALS) are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="tardbp-als.Resources">
        <title>Resources</title>
      </sec>
      <sec id="tardbp-als.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">TARDBP</italic> has six exons, five of which are coding. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="tardbp-als" object-id="tardbp-als.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> More than 35 <italic toggle="yes">TARDBP</italic> coding variants have been identified in familial (FALS) and/or simplex cases of ALS (SALS). The majority of these variants have been identified in single simplex cases or in probands of families for which segregation data are unavailable. The argument for the pathogenicity of these variants has historically stood on their location (within exon 6 near clearly causative pathogenic variants) and their absence in control subjects (usually a modest number). This fact could suggest a high percentage of private (i.e., unique) variants in <italic toggle="yes">TARDBP-</italic>related ALS [<xref ref-type="bibr" rid="tardbp-als.REF.corrado.2009.688">Corrado et al 2009</xref>].</p>
        <p>However, exome and genome sequencing in large non-ALS populations, such as the 1000 Genomes Project or ExAC browser, have identified infrequent and rare coding variants across <italic toggle="yes">TARDBP,</italic> including some within exon 6. In fact, six variants previously identified in patients with ALS are now found in these databases (but always in &#x0003c;1 in 30,000 individuals). Determining the significance of this group of variants is difficult in the absence of additional genetic data (e.g., additional cases or segregation within a family). A clear classification as pathogenic or benign may not be possible until functional assays are developed that reliably distinguish between these groups.</p>
        <p>Evidence for pathogenicity is much clearer for a minority of published variants (<xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">Table 2</xref>). Some have been found in more than one family or simplex case (p.Asn267Ser; p.Gly287Ser; p.Ala315Thr; p.Met337Val; p.Asn352Ser) or have been found in both FALS and SALS cases (p.Gly294Val; p.Gly295Ser; p.Gly348Cys; p.Ala382Thr). All clearly pathogenic variants affect highly conserved amino acids and reside in exon 6. This finding may be biased because exon 6 has often been selectively resequenced.</p>
        <p>Two non-exon 6 variants are <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Asp169Gly</xref> (in exon 4) [<xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>] and the 3&#x02019; UTR variant <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">1462T&#x0003e;C</xref> [<xref ref-type="bibr" rid="tardbp-als.REF.daoud.2009.112">Daoud et al 2009</xref>]. However, each has been found in only one individual with SALS, making it unclear if these are truly pathogenic. Only one pathogenic nonsense variant has been described to date (a single base-pair duplication-producing frameshift and a premature stop codon p.Tyr374Ter [<xref ref-type="bibr" rid="tardbp-als.REF.daoud.2009.112">Daoud et al 2009</xref>]).</p>
        <p><bold>Benign variants.</bold> Given the complexities of distinguishing benign from pathogenic rare variants, the interpretation of the p.Ala90Val variant has been particularly challenging. The <xref ref-type="table" rid="tardbp-als.T.tardbp_variants_discussed_i">p.Ala90Val</xref> variant was originally found in an individual with FTLD-MND [<xref ref-type="bibr" rid="tardbp-als.REF.winton.2008.2252">Winton et al 2008</xref>], but has subsequently been seen in other patient cohorts. However, it is also consistently found in controls of northern European background as well [<xref ref-type="bibr" rid="tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.sreedharan.2008.1668">Sreedharan et al 2008</xref>]. By genetic evidence alone, it is therefore likely to be benign. However, experimental data suggest that this allele causes abnormal cytoplasmic aggregation of TDP-43 [<xref ref-type="bibr" rid="tardbp-als.REF.winton.2008.2252">Winton et al 2008</xref>], and therefore it remains possible that the p.Ala90Val substitution may convey susceptibility to developing FTD/ALS.</p>
        <table-wrap id="tardbp-als.T.tardbp_variants_discussed_i" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p><italic toggle="yes">TARDBP</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Uncertain Significance</bold>
                </td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.269C&#x0003e;T</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala90Val&#x000a0;<sup>2,&#x000a0;3</sup></td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_4" rowspan="14" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/42741653">NM_007375.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/6678271">NP_031401.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.506A&#x0003e;G</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp169Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1121dup</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr374Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.*83T&#x0003e;C&#x000a0;<sup>4</sup><break/>(1462T&#x0003e;C)</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(3&#x02019; untranslated region)</td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" rowspan="10" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.800A&#x0003e;G</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn267Ser&#x000a0;<sup>3,&#x000a0;5</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.859G&#x0003e;A</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly287Ser&#x000a0;<sup>3,&#x000a0;5</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.881G&#x0003e;T</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly294Val&#x000a0;<sup>3,&#x000a0;6,&#x000a0;7</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.883G&#x0003e;A</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly295Ser&#x000a0;<sup>6,&#x000a0;7</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.892G&#x0003e;A</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly298Ser&#x000a0;<sup>5,&#x000a0;7</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.943G&#x0003e;A</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala315Thr&#x000a0;<sup>5,&#x000a0;8</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1009A&#x0003e;G</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met337Val&#x000a0;<sup>5,&#x000a0;8</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1042G&#x0003e;T</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly348Cys&#x000a0;<sup>5,&#x000a0;6</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1055A&#x0003e;G</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn352Ser&#x000a0;<sup>5</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1144G&#x0003e;A</td>
                <td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala382Thr&#x000a0;<sup>5,&#x000a0;6,&#x000a0;9</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="tardbp-als.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="tardbp-als.TF.2.2">
              <label>2. </label>
              <p>May be a variant that is normal or may confer susceptibility to FTD/ALS</p>
            </fn>
            <fn id="tardbp-als.TF.2.3">
              <label>3. </label>
              <p>Variant is also rarely found in population controls.</p>
            </fn>
            <fn id="tardbp-als.TF.2.4">
              <label>4. </label>
              <p>* indicates location in 3&#x02019;UTR and number of nucleotides beyond the normal stop codon.</p>
            </fn>
            <fn id="tardbp-als.TF.2.5">
              <label>5. </label>
              <p>Identified in affected individuals in more than one family</p>
            </fn>
            <fn id="tardbp-als.TF.2.6">
              <label>6. </label>
              <p>Identified in both FALS and SALS</p>
            </fn>
            <fn id="tardbp-als.TF.2.7">
              <label>7. </label>
              <p>Limited evidence of segregation</p>
            </fn>
            <fn id="tardbp-als.TF.2.8">
              <label>8. </label>
              <p>Convincing evidence of segregation</p>
            </fn>
            <fn id="tardbp-als.TF.2.9">
              <label>9. </label>
              <p>Familial and simplex cases share founder haplotype.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="tardbp-als-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf) for a more complete list of <italic toggle="yes">TARDBP</italic> variants of uncertain clinical significance.</p>
        <p><bold>Normal gene product.</bold> TDP-43 comprises 414 amino acids encoded by <italic toggle="yes">TARDBP</italic> exons 2-6. TDP-43 is a ubiquitously expressed nuclear protein with structural similarities to the hnRNP A/B family of RNA binding proteins and is known to regulate DNA transcription, alternative splicing, and mRNA stability [<xref ref-type="bibr" rid="tardbp-als.REF.buratti.2008.867">Buratti &#x00026; Baralle 2008</xref>]. Although information regarding the role of TDP-43 in normal cellular function is limited, both loss of function and overexpression are deleterious in a wide variety of cellular contexts in vitro and in vivo [<xref ref-type="bibr" rid="tardbp-als.REF.baloh.2011.3539">Baloh 2011</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Most of the clearly pathogenic variants thus far identified are located in exon 6. These cluster in the C-terminal glycine-rich domain of the TDP-43, an area that interacts with other hnRNPs to regulate alternative splicing [<xref ref-type="bibr" rid="tardbp-als.REF.buratti.2005.37572">Buratti et al 2005</xref>] but is also critically involved in TDP-43 self-aggregation and has properties similar to prion-related domains in yeast [<xref ref-type="bibr" rid="tardbp-als.REF.cushman.2010.1191">Cushman et al 2010</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.udan.2011.1">Udan &#x00026; Baloh 2011</xref>]. In <italic toggle="yes">TARDBP</italic>-related ALS, TDP-43 positive aggregates are phosphorylated and ubiquitinated, and are present in both the cytoplasm and the nucleus. Because a decrease in normal nuclear TDP-43 staining is often seen in these cells, loss of function has also been proposed to play a role in disease [<xref ref-type="bibr" rid="tardbp-als.REF.neumann.2006.130">Neumann et al 2006</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.davidson.2007.521">Davidson et al 2007</xref>]. While pathogenic variants in <italic toggle="yes">TARDBP</italic> have been shown to influence TDP-43 proteolysis and aggregation, the exact role they play in promoting ALS remains poorly understood [<xref ref-type="bibr" rid="tardbp-als.REF.baloh.2012.701">Baloh 2012</xref>].</p>
        <p>Importantly, TDP-43 positive inclusions are not specific to ALS, and are found in numerous other neurodegenerative diseases [<xref ref-type="bibr" rid="tardbp-als.REF.freeman.2008.62">Freeman et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.uryu.2008.555">Uryu et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.arai.2009.125">Arai et al 2009</xref>] as well as several diseases of muscle [<xref ref-type="bibr" rid="tardbp-als.REF.weihl.2008.1186">Weihl et al 2008</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.k_sters.2009.209">K&#x000fc;sters et al 2009</xref>, <xref ref-type="bibr" rid="tardbp-als.REF.oliv_.2009.262">Oliv&#x000e9; et al 2009</xref>].</p>
      </sec>
      <sec id="tardbp-als.References">
        <title>References</title>
        <sec id="tardbp-als.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="tardbp-als.Literature_Cited.reflist0">
            <ref id="tardbp-als.REF.arai.2009.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonoka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niizato</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuchiya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iritani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onaya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.</article-title>
                <source>Acta Neuropathol</source>
                <volume>117</volume>
                <fpage>125</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">19139911</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.baloh.2011.3539">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.</article-title>
                <source>FEBS J.</source>
                <volume>278</volume>
                <fpage>3539</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">21777387</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.baloh.2012.701">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?</article-title>
                <source>Curr Opin Neurol.</source>
                <volume>25</volume>
                <fpage>701</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23041957</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.b_umer.2009.1283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>B&#x000e4;umer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkinson</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talbot</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2009</year>
                <volume>80</volume>
                <fpage>1283</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19864663</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.benajiba.2009.470">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benajiba</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Ber</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacoste</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas-Anterion</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couratier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legallic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salachas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannequin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decousus</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacomblez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guedj</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golfier</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubois</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campion</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meininger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>French Clinical and Genetic Research Network on Frontotemporal Lobar Degeneration/Frontotemporal Lobar Degeneration with Motoneuron Disease</collab>
                </person-group>
                <article-title>TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration.</article-title>
                <source>Ann Neurol</source>
                <year>2009</year>
                <volume>65</volume>
                <fpage>470</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">19350673</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.borghero.2011.2327.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Borghero</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Floris</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marrosu</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murru</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costantino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parish</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pugliatti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ticca</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cammarosano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moglia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cistaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Restagno</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chi&#x000f2;</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD.</article-title>
                <source>Neurobiol Aging.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>2327.e1</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21803454</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.borroni.2010.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Borroni</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Archetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Bo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonvicini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agosti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosseddu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turla</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Lorenzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietro Comi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennarelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padovani</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course.</article-title>
                <source>Rejuvenation Res.</source>
                <year>2010</year>
                <volume>13</volume>
                <fpage>509</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">20645878</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.brooks.2000.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brooks</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swash</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munsat</surname>
                    <given-names>TL</given-names>
                  </name>
                  <collab>World Federation of Neurology Research Group on Motor Neuron Diseases</collab>
                </person-group>
                <year>2000</year>
                <article-title>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.</article-title>
                <source>Amyotroph Lateral Scler Other Motor Neuron Disord</source>
                <volume>1</volume>
                <fpage>293</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11464847</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.buratti.2008.867">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baralle</surname>
                    <given-names>FE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease.</article-title>
                <source>Front Biosci</source>
                <volume>13</volume>
                <fpage>867</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">17981595</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.buratti.2005.37572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brindisi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giombi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tisminetzky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayala</surname>
                    <given-names>YM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baralle</surname>
                    <given-names>FE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing.</article-title>
                <source>J Biol Chem</source>
                <volume>280</volume>
                <fpage>37572</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">16157593</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.corcia.2012.1519">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corcia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valdmanis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millecamps</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lionnet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blasco</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouzat</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daoud</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belzil</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pageot</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danel-Brunaud</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandenberghe</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pradat</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couratier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salachas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lumbroso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meininger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camu</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations.</article-title>
                <source>Neurology.</source>
                <year>2012</year>
                <volume>78</volume>
                <fpage>1519</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">22539580</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.corrado.2009.688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corrado</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gellera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellotti</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlomagno</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ticozzi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taroni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baralle</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silani</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Alfonso</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis.</article-title>
                <source>Hum Mutat</source>
                <volume>30</volume>
                <fpage>688</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19224587</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.cushman.2010.1191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cushman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>OD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitler</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shorter</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Prion-like disorders: blurring the divide between transmissibility and infectivity.</article-title>
                <source>J Cell Sci.</source>
                <volume>123</volume>
                <fpage>1191</fpage>
                <lpage>201</lpage>
                <pub-id pub-id-type="pmid">20356930</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.daoud.2009.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daoud</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valdmanis</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabashi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupr&#x000e9;</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meininger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis.</article-title>
                <source>J Med Genet</source>
                <volume>46</volume>
                <fpage>112</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18931000</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.davidson.2007.521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pickering-Brown</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du Plessis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neary</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snowden</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.</article-title>
                <source>Acta Neuropathol</source>
                <volume>113</volume>
                <fpage>521</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">17219193</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.del_bo.2009.727">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Del Bo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghezzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandolfo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranieri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghione</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prelle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orsetti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorar&#x000f9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siciliano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresolin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <article-title>TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations.</article-title>
                <source>Eur J Neurol</source>
                <year>2009</year>
                <volume>16</volume>
                <fpage>727</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">19236453</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.farrero.2005.2132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farrero</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prats</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Povedano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Matos</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manresa</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escarrabill</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement.</article-title>
                <source>Chest</source>
                <volume>127</volume>
                <fpage>2132</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15947331</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.floris.2015.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Floris</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borghero</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Stefano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murru</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corongiu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuccu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranquilli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherchi</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marrosu</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chi&#x000f2;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marrosu</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations.</article-title>
                <source>J Neurol.</source>
                <volume>262</volume>
                <fpage>375</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">25408367</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.freeman.2008.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Freeman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spires-Jones</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyman</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Growdon</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frosch</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TAR-DNA binding protein 43 in Pick disease.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>67</volume>
                <fpage>62</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18091558</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.gijselinck.2009.1329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gijselinck</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sleegers</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelborghs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robberecht</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandenberghe</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sciot</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dermaut</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goossens</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Zee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Pooter</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del-Favero</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santens</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Deyn</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruts</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.</article-title>
                <source>Neurobiol Aging.</source>
                <year>2009</year>
                <volume>30</volume>
                <fpage>1329</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">18068872</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.gitcho.2008.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gitcho</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraverty</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norton</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levitch</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatanpaa</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>CL</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Bigio</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caselli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Lozi</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pestronk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rademakers</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goate</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cairns</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 A315T mutation in familial motor neuron disease.</article-title>
                <source>Ann Neurol</source>
                <volume>63</volume>
                <fpage>535</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18288693</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.gordon.2007.1045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florence</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verheijde</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doorish</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spitalny</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacArthur</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsumoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neville</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boylan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mozaffar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belsh</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravits</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedlack</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graves</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCluskey</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tandan</surname>
                    <given-names>R</given-names>
                  </name>
                  <collab>Western ALS Study Group</collab>
                </person-group>
                <article-title>Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.</article-title>
                <source>Lancet Neurol.</source>
                <year>2007</year>
                <volume>6</volume>
                <fpage>1045</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">17980667</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.grosskreutz.2008.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grosskreutz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peschel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unrath</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dengler</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludolph</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kassubek</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders.</article-title>
                <source>Amyotroph Lateral Scler</source>
                <volume>9</volume>
                <fpage>238</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">18608107</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.guerreiro.2008.e2450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guerreiro</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schymick</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crews</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis.</article-title>
                <source>PLoS ONE</source>
                <volume>3</volume>
                <fpage>e2450</fpage>
                <pub-id pub-id-type="pmid">18545701</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.kabashi.2008.572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kabashi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valdmanis</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegelman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McConkey</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vande Velde</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacomblez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pochigaeva</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salachas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pradat</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meininger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupre</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.</article-title>
                <source>Nat Genet</source>
                <volume>40</volume>
                <fpage>572</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18372902</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.kasai.2009.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kasai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishigami</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasayama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foulds</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawa</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.</article-title>
                <source>Acta Neuropathol</source>
                <volume>117</volume>
                <fpage>55</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">18989684</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.k_hnlein.2008.1185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>K&#x000fc;hnlein</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperfeld</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanmassenhove</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Deerlin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kretzschmar</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludolph</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations.</article-title>
                <source>Arch Neurol</source>
                <volume>65</volume>
                <fpage>1185</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18779421</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.k_sters.2009.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>K&#x000fc;sters</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Hoeve</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schelhaas</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ter Laak</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lammens</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>TDP-43 accumulation is common in myopathies with rimmed vacuoles.</article-title>
                <source>Acta Neuropathol</source>
                <volume>117</volume>
                <fpage>209</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">19066918</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.miller.2009a.1218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasarskis</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>England</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forshew</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalra</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsumoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoesmith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolley</surname>
                    <given-names>SC</given-names>
                  </name>
                  <collab>Quality Standards Subcommittee of the American Academy of Neurology</collab>
                </person-group>
                <article-title>Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</article-title>
                <source>Neurology.</source>
                <year>2009a</year>
                <volume>73</volume>
                <fpage>1218</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">19822872</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.miller.2009b.1227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasarskis</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>England</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forshew</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalra</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsumoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoesmith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolley</surname>
                    <given-names>SC</given-names>
                  </name>
                  <collab>Quality Standards Subcommittee of the American Academy of Neurology</collab>
                </person-group>
                <article-title>Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment(an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</article-title>
                <source>Neurology.</source>
                <year>2009b</year>
                <volume>73</volume>
                <fpage>1227</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">19822873</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.miller.2007.cd001447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).</article-title>
                <source>Cochrane Database Syst Rev.</source>
                <volume>3</volume>
                <fpage>CD001447</fpage>
                <pub-id pub-id-type="pmid">17253460</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.neumann.2006.130">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sampathu</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwong</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Truax</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Micsenyi</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruce</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCluskey</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masliah</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feiden</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kretzschmar</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</article-title>
                <source>Science</source>
                <volume>314</volume>
                <fpage>130</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17023659</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.nozaki.2010.1209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nozaki</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamaguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshikawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muroishi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi-Shinohara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itokawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Familial ALS with G298S mutation in TARDBP: a comparison of CSF tau protein levels with those in sporadic ALS.</article-title>
                <source>Intern Med.</source>
                <year>2010</year>
                <volume>49</volume>
                <fpage>1209</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">20558945</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.oliv_.2009.262">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oliv&#x000e9;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janu&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e1;mez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torrej&#x000f3;n-Escribano</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>68</volume>
                <fpage>262</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">19225410</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.orr_.2012.172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orr&#x000f9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manolakos</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orr&#x000f9;</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kokotas</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mascia</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carcassi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <article-title>High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with amyotrophic lateral sclerosis.</article-title>
                <source>Clin Genet.</source>
                <year>2012</year>
                <volume>81</volume>
                <fpage>172</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21418058</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.pamphlett.2009.222">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pamphlett</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luquin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jew</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations.</article-title>
                <source>Neuropathol Appl Neurobiol</source>
                <volume>35</volume>
                <fpage>222</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18986339</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.rayaprolu.2013.312">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rayaprolu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujioka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soto-Ortolaza</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rademakers</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boylan</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graff-Radford</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitti</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wszolek</surname>
                    <given-names>ZK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>OA</given-names>
                  </name>
                </person-group>
                <article-title>TARDBP mutations in Parkinson's disease.</article-title>
                <source>Parkinsonism Relat Disord.</source>
                <year>2013</year>
                <volume>19</volume>
                <fpage>312</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">23231971</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.rutherford.2008.e1000193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rutherford</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gass</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finch</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>YF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuntz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crook</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sreedharan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorenson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lippa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bigio</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geschwind</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knopman</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsumoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cashman</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boylan</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boeve</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graff-Radford</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wszolek</surname>
                    <given-names>ZK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caselli</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rademakers</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis.</article-title>
                <source>PLoS Genet</source>
                <volume>4</volume>
                <fpage>e1000193</fpage>
                <pub-id pub-id-type="pmid">18802454</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.sreedharan.2008.1668">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sreedharan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>IP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tripathi</surname>
                    <given-names>VB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogelj</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durnall</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baralle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Belleroche</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Chalabi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.</article-title>
                <source>Science</source>
                <volume>319</volume>
                <fpage>1668</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">18309045</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.steinacker.2008.1481">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinacker</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendrich</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperfeld</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jesse</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Arnim</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uttner</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tumani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kretzschmar</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludolph</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</article-title>
                <source>Arch Neurol</source>
                <volume>65</volume>
                <fpage>1481</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19001167</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.synofzik.2014.1212.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Synofzik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Born</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rominger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lummel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000f6;ls</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biskup</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;le</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grasshoff</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopstock</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adamczyk</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease.</article-title>
                <source>Neurobiol Aging.</source>
                <year>2014</year>
                <volume>35</volume>
                <fpage>1212.e1</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">24300238</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.traynor.2000.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Codd</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corr</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forde</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frost</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardiman</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Amyotrophic lateral sclerosis mimic syndromes: a population-based study.</article-title>
                <source>Arch Neurol</source>
                <volume>57</volume>
                <fpage>109</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">10634456</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.udan.2011.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Udan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Implications of the prion-related Q/N domains in TDP-43 and FUS.</article-title>
                <source>Prion.</source>
                <volume>5</volume>
                <fpage>1</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21135580</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.uryu.2008.555">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Uryu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakashima-Yasuda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forman</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwong</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kretzschmar</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Concomitant TAR-DNA-binding protein 43 is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>67</volume>
                <fpage>555</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">18520774</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.van_deerlin.2008.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Deerlin</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leverenz</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bekris</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elman</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clay</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen-Plotkin</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Lage</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinbart</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCluskey</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalb</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galasko</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montine</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schellenberg</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.</article-title>
                <source>Lancet Neurol</source>
                <volume>7</volume>
                <fpage>409</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">18396105</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.van_blitterswijk.2012.3776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Blitterswijk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Es</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dooijes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rheenen</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourque</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schelhaas</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Kooi</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Visser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bakker</surname>
                    <given-names>PI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veldink</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <article-title>Evidence for an oligogenic basis of amyotrophic lateral sclerosis.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>3776</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">22645277</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.weihl.2008.1186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weihl</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temiz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanson</surname>
                    <given-names>PI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimonis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pestronk</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>79</volume>
                <fpage>1186</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18796596</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.winton.2008.2252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winton</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Deerlin</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwong</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schellenberg</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rademakers</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caselli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karydas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojanowski</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro.</article-title>
                <source>FEBS Lett</source>
                <volume>582</volume>
                <fpage>2252</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18505686</pub-id>
              </element-citation>
            </ref>
            <ref id="tardbp-als.REF.yokoseki.2008.538">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yokoseki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koyama</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeuchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kakita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishizawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onodera</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TDP-43 mutation in familial amyotrophic lateral sclerosis.</article-title>
                <source>Ann Neurol</source>
                <volume>63</volume>
                <fpage>538</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">18438952</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="tardbp-als.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="tardbp-als.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cedars-sinai.edu/Research/Research-Labs/Baloh-Lab/">Baloh Laboratory</ext-link>
          </p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://millerlaboratory.wustl.edu/">Miller Laboratory</ext-link>
          </p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://neuromuscular.wustl.edu/">Neuromuscular Disease Center</ext-link>
          </p>
        </sec>
        <sec id="tardbp-als.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>12 March 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 May 2009 (cd) Revision: prenatal testing available</p>
            </list-item>
            <list-item>
              <p>23 April 2009 (et) Review posted live</p>
            </list-item>
            <list-item>
              <p>14 November 2008 (rhb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
